SCHEMBL760722

SCHEMBL760722

COC(=O)c1cc(Br)cc2cn[nH]c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.47
MAPT P10636 3/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PLK4 O00444 1/20 0.39
CHEK1 O14757 1/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
MAP4K4 O95819 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
FGFR1 P11362 1/20 0.39
PDGFRA P16234 1/20 0.39
LTK P29376 1/20 0.39
KDR P35968 1/20 0.39
MAP2K2 P36507 1/20 0.39
FLT3 P36888 1/20 0.39
CSNK1A1 P48729 1/20 0.39
PRKX P51817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1081287 0.83 TSHR (0.49) TSHRMAPTL3MBTL1PLK4CHEK1
SCHEMBL16939384 0.83 TSHR (0.49) TSHRMAPTPLK4CHEK1AURKA
SCHEMBL11577765 0.83 TSHR (0.49) TSHRMAPTL3MBTL1PLK4CHEK1
SCHEMBL1080968 0.82 TSHR (0.47) TSHRMAPTTDO2PLK4CHEK1
SCHEMBL18188461 0.82 TSHR (0.55) TSHRMAPTPLK4CHEK1AURKA
SCHEMBL28723060 0.82 TSHR (0.47) TSHRMAPTPLK4CHEK1AURKA
SCHEMBL4501756 0.81 PLK4 (0.42) IDO1TDO2PLK4CHEK1AURKA
SCHEMBL20487617 0.80 BTK (0.57) MAPTIDO1TDO2PLK4CHEK1
SCHEMBL16929719 0.78 TSHR (0.44) TSHRMAPTL3MBTL1PLK4CHEK1
SCHEMBL25375534 0.77 AXL (0.48) TSHRMAPTPLK4CHEK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF MAZE THERAPEUTICS INC (US) 2025-10-16 US disclosed
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 US disclosed
US-20250179017-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2025-06-05 US disclosed
WO-2025111547-A1 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF RGENTA THERAPEUTICS, INC. (US) 2025-05-30 WO disclosed
EP-3589628-B1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2025-05-07 EP disclosed
WO-2025090658-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-05-01 WO disclosed
CN-119487006-A Amide compounds as PGE2 receptor antagonists 广东新契生物医药科技有限公司 2025-02-18 CN disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 US disclosed
EP-4493562-A1 TYK2 INHIBITORS AND USES THEREOF Alumis Inc. (US) 2025-01-22 EP disclosed
CN-101541809-A Spiroketone acetyl-CoA carboxylase inhibitors PFIZER PROD INC (US) 2009-09-23 CN disclosed
CN-101426779-A Pesticide containing bicyclic bisamide structure SYNGENTA PARTICIPATIONS AG (CH) 2009-05-06 CN disclosed
EP-2001480-A2 INDAZOLE COMPOUNDS Abbott Laboratories (US) 2008-12-17 EP disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179017-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS PTGER1, PTGER2, CNR2 TSHR 489/4885MAPT 4689/4885IDO1 1495/4885
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF CDK2, CDK20, CDK1 TSHR 2513/4885MAPT 3329/4885IDO1 1746/4885
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 TSHR 2823/4885MAPT 2375/4885IDO1 104/4885
US-20070281933-A1 Novel Indazole Carboxamides And Their Use IKBKG, IRAK2, NFKBIA TSHR 3814/4885MAPT 3416/4885IDO1 38/4885
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF APOL1, APOB, LDLR TSHR 1719/4885MAPT 431/4885IDO1 2479/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 TSHR 936/4885MAPT 4730/4885IDO1 1260/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 TSHR 936/4885MAPT 4730/4885IDO1 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.